Inactive Instrument

Mitsubishi Tanabe Pharma Corporation Stock

4508

JP3469000008

Chart Mitsubishi Tanabe Pharma Corporation

Duration

Period

Style

Dynamic Chart

Latest news about Mitsubishi Tanabe Pharma Corporation

Grand Pharmaceutical Co., Ltd. entered into an equity acquisition agreement to acquire 75.35% stake in Tianjin Tanabe Seiyaku Co. Ltd. from Mitsubishi Tanabe Pharma Corporation for approximately HKD 400 million.	Dec. 20	CI
Certain Options of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Certain Warrants of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Certain Common Stock of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of Radicava Ors®, an Oral Treatment for Als	22-06-01	CI
Mitsubishi Tanabe Pharma Corporation Announces Regulatory Approval of Dysval® (Valbenazine) for the Treatment of Tardive Dyskinesia in Japan	22-03-28	CI
Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details At Virtual 32nd International Symposium on ALS/MND	21-12-10	CI
Mitsubishi Tanabe Pharma Corporation Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-04	CI
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ is Now Available in the U.S. for the Treatment of ALS	21-06-30	CI
Mitsubishi Tanabe Pharma Corporation Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities	21-03-17	CI
Transcript : Mitsubishi Tanabe Pharma Corporation - Special Call	21-03-02
Pharma Foods International Co., Ltd. Enters into Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for A New Therapeutic Antibody to Treat Autoimmune Diseases	21-01-26	CI
Mitsubishi Tanabe Pharma Corporation Announces Board Changes	20-02-25	CI
Transcript : Mitsubishi Tanabe Pharma Corporation, Q3 2020 Earnings Call, Feb 04, 2020	20-02-04
Mitsubishi Tanabe Pharma Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Year Ending March 31, 2020	20-02-04	CI

More news

Analyst Recommendations on Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation Presents Data on ALS Functional Rating Scale-Revised

16-12-09

More recommendations

Press releases Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma : Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec	20-04-29	AQ
Mitsubishi Tanabe Pharma : Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (Edaravone)	20-04-22	AQ
Aytu BioScience : Announces Exclusive ZolpiMist License to Commercialize Aytu's Oral Spray Sleep Aid in South Korea	20-04-09	AQ
Mitsubishi Tanabe Pharma : Announcement of FY2019 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"	20-02-04	PU
Mitsubishi Tanabe Pharma : Announcement of FY2019 2nd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"	19-10-30	PU

More press releases

News in other languages on Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma : acquiert l'israélien Neuroderm pour $1,1 md	17-07-24
Mitsubishi Tanabe Pharma rachète l'israélien NeuroDerm pour 1,1 mrd USD	17-07-24
Mitsubishi Tanabe Pharma soumet son traitement contre la maladie de Charcot	16-06-21
Mitsubishi Tanabe Pharma : Amgen acquiert Dezima Pharma pour $300 mlns	15-09-16

More news

Managers and Directors - Mitsubishi Tanabe Pharma Corporation

Managers	Title	Age	Since
Akihiro Tsujimura CEO	Chief Executive Officer	56	-
Hiroaki Ueno CEO	Chief Executive Officer	65	07-09-30
Megumi Otaki CMP	Compliance Officer	-	-

Members of the board	Title	Age	Since
Eizou Tabaru ADM	Chief Administrative Officer	65	14-03-31
Ken Fujiwara BRD	Director/Board Member	63	-
Hiroaki Ueno CEO	Chief Executive Officer	65	07-09-30

More insiders

Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The medical supplies business is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Company's subsidiaries receive raw materials from the company and sell products locally.

Sector

More about the company